LS007, a potent and orally bioavailable CDK9 inhibitor, suppresses the growth of triple-negative and estrogen receptor-positive breast cancer

被引：0
|
作者：
Rahaman, Muhammed Hamidur [1 ]
Zhang, Yinghui [1 ]
Islam, Md Saiful [1 ]
Heinemann, Gary [1 ]
Anshabo, Abel Tesfaye [1 ]
Albrecht, Hugo [1 ]
Milne, Robert [1 ]
Wang, Shudong [1 ]
机构：
[1] Univ South Australia, Adelaide, SA, Australia
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-4427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4427
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
    Aditya Bardia
    Ayca Gucalp
    Noashir DaCosta
    Nashat Gabrail
    Michael Danso
    Haythem Ali
    Kimberly L. Blackwell
    Lisa A. Carey
    Joel R. Eisner
    Edwina S. Baskin-Bey
    Tiffany A. Traina
    Breast Cancer Research and Treatment, 2018, 171 : 111 - 120
  • [22] Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
    Bardia, Aditya
    Gucalp, Ayca
    DaCosta, Noashir
    Gabrail, Nashat
    Danso, Michael
    Ali, Haythem
    Blackwell, Kimberly L.
    Carey, Lisa A.
    Eisner, Joel R.
    Baskin-Bey, Edwina S.
    Traina, Tiffany A.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 111 - 120
  • [23] A potent and orally available tubulin inhibitor ABI-231 suppresses triple negative breast cancer tumor growth and metastasis
    Deng, Shanshan
    Krutilina, Raya
    Wang, Qinghui
    Seagroves, Tiffany N.
    Miller, Duane D.
    Li, Wei
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer
    Hollmen, Maija
    Roudnicky, Filip
    Karaman, Sinem
    Detmar, Michael
    SCIENTIFIC REPORTS, 2015, 5
  • [25] Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer
    Maija Hollmén
    Filip Roudnicky
    Sinem Karaman
    Michael Detmar
    Scientific Reports, 5
  • [26] Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer
    Bae, Soo Youn
    Kim, Sangmin
    Lee, Jun Ho
    Lee, Hyun-chul
    Lee, Se Kyung
    Kil, Won Ho
    Kim, Seok Won
    Lee, Jeong Eon
    Nam, Seok Jin
    BMC CANCER, 2015, 15
  • [27] Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer
    Guo, Liying
    Zhu, Qianwen
    Aisimutuola, Mulati
    Yilamu, Dilimina
    Liu, Sha
    Jakulin, Adina
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (06) : 2147 - 2150
  • [28] Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines
    Taghizadeh, Bita
    Ghavami, Laleh
    Nikoofar, Alireza
    Goliaei, Bahram
    BREAST CANCER, 2015, 22 (04) : 382 - 390
  • [29] Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
    Tria, George S.
    Abrams, Tinya
    Baird, Jason
    Burks, Heather E.
    Firestone, Brant
    Gaither, L. Alex
    Hamann, Lawrence G.
    He, Guo
    Kirby, Christina A.
    Kim, Sunkyu
    Lombardo, Franco
    Macchi, Kaitlin J.
    McDonnell, Donald P.
    Mishina, Yuji
    Norris, John D.
    Nunez, Jill
    Springer, Clayton
    Sun, Yingchuan
    Thomsen, Noel M.
    Wang, Chunrong
    Wang, Jianling
    Yu, Bing
    Tiong-Yip, Choi-Lai
    Peukert, Stefan
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 2837 - 2864
  • [30] Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines
    Bita Taghizadeh
    Laleh Ghavami
    Alireza Nikoofar
    Bahram Goliaei
    Breast Cancer, 2015, 22 : 382 - 390
12345